Sight Pharma

About Sight Pharma

Sight Sciences, Inc. operates as a medical technology company with a clear focus on addressing the underlying causes of highly prevalent eye diseases. The company was founded by brothers Paul Badawi and David Badawi in 2006, establishing its headquarters in Menlo Park, California, a prominent hub for medical technology. Paul Badawi serves as the Chief Executive Officer, while Dr. David Badawi, MD, is the Chief Technology Officer, combining business leadership with deep clinical insight.

The company’s business model centers on the development and commercialization of surgical systems for ophthalmological diseases, generating revenue through the sale of these specialized devices directly to eye care professionals. Sight Sciences has a dual focus, targeting both glaucoma and dry eye disease, two of the largest segments in the eyecare market. This strategy diversifies its market approach and addresses significant unmet needs in patient care. The company's financial model is characterized by a high gross margin, reported at 83% in the third quarter of 2024, though this is offset by substantial investments in sales, marketing, and research and development to drive market adoption and continued product development.

Sight Sciences offers two primary products: the OMNI® Surgical System and the TearCare® System. The OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device used for canaloplasty to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The TearCare System is designed to treat Meibomian Gland Dysfunction (MGD), a principal cause of evaporative dry eye disease. A key milestone was the FDA 510(k) clearance for the OMNI Surgical System in 2018, followed by clearance for the TearCare System in 2019, which enabled commercial launches into these respective markets. The company achieved another significant step in 2021 with its Initial Public Offering (IPO) on Nasdaq, raising substantial capital to fund commercial expansion and further research.